In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity

IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Therapeutic Advances in Endocrinology and Metabolism Pub Date : 2022-01-01 DOI:10.1177/20420188221093220
M. Al-Badri, Cara L. Kilroy, J. Shahar, Shaheen Tomah, Hannah Gardner, Mallory Sin, Jennie Votta, Aliza Phillips-Stoll, Aaron Price, J. Beaton, C. Davis, Jo-Anne M. Rizzotto, Shilton Dhaver, O. Hamdy
{"title":"In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity","authors":"M. Al-Badri, Cara L. Kilroy, J. Shahar, Shaheen Tomah, Hannah Gardner, Mallory Sin, Jennie Votta, Aliza Phillips-Stoll, Aaron Price, J. Beaton, C. Davis, Jo-Anne M. Rizzotto, Shilton Dhaver, O. Hamdy","doi":"10.1177/20420188221093220","DOIUrl":null,"url":null,"abstract":"Background: Intensive lifestyle intervention (ILI) is essential for diabetes management. The Weight Achievement and Intensive Treatment (Why WAIT) program is a 12-week multidisciplinary weight management program that has been implemented in real-world clinical practice since 2005 and has shown long-term maintenance of weight reduction for 5 and 10 years. During the COVID-19 pandemic, the program went virtual using telemedicine and mobile health applications. Aims: This retrospective pilot study aims to evaluate the effectiveness of a virtual model of an already established and successful in-person program for diabetes and weight management since 2005. Methods: We evaluated 38 patients with diabetes and obesity enrolled in the Why WAIT program between February 2019 and December 2020. Sixteen participants were enrolled in virtual program (VP) and were compared with 22 participants who completed the latest two physical programs (PPs) before COVID-19. We evaluated changes in body weight, A1C, blood pressure (BP), and lipid profile after 12 weeks of ILI. Results: Body weight decreased by −7.4 ± 3.6 kg from baseline in VP compared with −6.8 ± 3.5 kg in PP (p = 0.6 between groups). A1C decreased by −1.03% ± 1.1% from baseline in VP, and by −1.0% ± 1.2% in PP (p = 0.9 between groups). BP, lipid profile, and all other parameters improved in both groups with no significant difference between them. Conclusion: Virtual multidisciplinary ILI is as effective as the in-person intervention program in improving body weight, A1C, BP, and lipid profile, and in reducing the number of anti-hyperglycemic medications. Results from our study suggest that scaling the Why WAIT program in a virtual format to a larger population of patients with diabetes and obesity is feasible and is potentially as successful as the in-person program.","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Endocrinology and Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420188221093220","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 8

Abstract

Background: Intensive lifestyle intervention (ILI) is essential for diabetes management. The Weight Achievement and Intensive Treatment (Why WAIT) program is a 12-week multidisciplinary weight management program that has been implemented in real-world clinical practice since 2005 and has shown long-term maintenance of weight reduction for 5 and 10 years. During the COVID-19 pandemic, the program went virtual using telemedicine and mobile health applications. Aims: This retrospective pilot study aims to evaluate the effectiveness of a virtual model of an already established and successful in-person program for diabetes and weight management since 2005. Methods: We evaluated 38 patients with diabetes and obesity enrolled in the Why WAIT program between February 2019 and December 2020. Sixteen participants were enrolled in virtual program (VP) and were compared with 22 participants who completed the latest two physical programs (PPs) before COVID-19. We evaluated changes in body weight, A1C, blood pressure (BP), and lipid profile after 12 weeks of ILI. Results: Body weight decreased by −7.4 ± 3.6 kg from baseline in VP compared with −6.8 ± 3.5 kg in PP (p = 0.6 between groups). A1C decreased by −1.03% ± 1.1% from baseline in VP, and by −1.0% ± 1.2% in PP (p = 0.9 between groups). BP, lipid profile, and all other parameters improved in both groups with no significant difference between them. Conclusion: Virtual multidisciplinary ILI is as effective as the in-person intervention program in improving body weight, A1C, BP, and lipid profile, and in reducing the number of anti-hyperglycemic medications. Results from our study suggest that scaling the Why WAIT program in a virtual format to a larger population of patients with diabetes and obesity is feasible and is potentially as successful as the in-person program.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
面对面和虚拟多学科强化生活方式干预对2型糖尿病和肥胖患者同样有效
背景:强化生活方式干预(ILI)是糖尿病管理的必要手段。体重实现和强化治疗(为什么等待)项目是一个为期12周的多学科体重管理项目,自2005年以来在现实世界的临床实践中实施,并显示出5年和10年的长期维持体重减轻。在2019冠状病毒病大流行期间,该项目通过远程医疗和移动医疗应用程序实现了虚拟。目的:本回顾性试点研究旨在评估自2005年以来已经建立并成功的糖尿病和体重管理现场项目的虚拟模型的有效性。方法:我们评估了2019年2月至2020年12月期间参加Why WAIT项目的38名糖尿病和肥胖症患者。16名参与者参加了虚拟项目(VP),并与22名在COVID-19之前完成了最近两个物理项目(PPs)的参与者进行了比较。我们评估了12周ILI后体重、糖化血红蛋白、血压(BP)和血脂的变化。结果:VP组的体重比基线下降了- 7.4±3.6 kg,而PP组的体重比基线下降了- 6.8±3.5 kg(组间p = 0.6)。与基线相比,VP组糖化血红蛋白下降了- 1.03%±1.1%,PP组糖化血红蛋白下降了- 1.0%±1.2%(组间p = 0.9)。两组血压、血脂及其他参数均有改善,两组间无显著差异。结论:虚拟多学科ILI在改善体重、糖化血红蛋白、血压和血脂水平以及减少降糖药物数量方面与现场干预方案同样有效。我们的研究结果表明,将“为什么等待”项目以虚拟形式扩展到更大的糖尿病和肥胖患者群体是可行的,并且可能与面对面的项目一样成功。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Therapeutic Advances in Endocrinology and Metabolism
Therapeutic Advances in Endocrinology and Metabolism Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
7.70
自引率
2.60%
发文量
42
审稿时长
8 weeks
期刊介绍: Therapeutic Advances in Endocrinology and Metabolism delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of endocrinology and metabolism.
期刊最新文献
Effect of bicalutamide on serum total testosterone concentration in transgender adults: a case series. Incidence and predictors of hyperglycemic emergencies among adult diabetic patients at public hospitals of Sidama Region and Gedeo Zone, Southern Ethiopia: a survival analysis. Diagnostic efficacy of aldosterone-to-renin ratio to screen primary aldosteronism in hypertension: a systemic review and meta-analysis. Ectopic corticotropin-releasing hormone syndrome caused by rectal large cell neuroendocrine carcinoma: a rare case report. Evaluating the precision and reliability of real-time continuous glucose monitoring systems in ambulatory settings: a systematic review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1